Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease by Chappell, Grace et al.
574
Introduction
Hepatocellular carcinoma (HCC) is a prevalent and life- 
threatening human cancer [1]. Importantly, the incidence 
of HCC continues to increase, while the incidence and 
death rates of many other cancers are steadily declining 
[1, 2]. In humans, the majority (70–90%) of HCC cases 
are concomitant with advanced liver fibrosis or cirrhosis 
[3]. The incidence of HCC in noncirrhotic liver is esti-
mated to be approximately 15–20% of all HCC cases, 
and only 10–12% in healthy livers. Liver fibrosis and 
cirrhosis associated with HCC are typically the conse-
quence of toxic insults, disturbances in metabolism, 
and/or viral infection [4].
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Abstract
Hepatocellular carcinoma (HCC) is a prevalent human cancer with rising in-
cidence worldwide. Human HCC is frequently associated with chronic liver 
inflammation and cirrhosis, pathophysiological processes that are a consequence 
of chronic viral infection, disturbances in metabolism, or exposure to chemical 
toxicants. To better characterize the pathogenesis of HCC, we used a human 
disease-relevant mouse model of fibrosis- associated hepatocarcinogenesis. In this 
model, marked liver tumor response caused by the promutagenic chemical 
 N-nitrosodiethylamine in the presence of liver fibrosis was associated with epi-
genetic events indicative of genomic instability. Therefore, we hypothesized that 
DNA copy number alterations (CNAs), a feature of genomic instability and a 
common characteristic of cancer, are concordant between human HCC and 
mouse models of fibrosis- associated hepatocarcinogenesis. We evaluated DNA 
CNAs and changes in gene expression in the mouse liver (normal, tumor, and 
nontumor fibrotic tissues). Additionally, we compared our findings to DNA 
CNAs in human HCC cases (tumor and nontumor cirrhotic/fibrotic tissues) 
using publicly available data from The Cancer Genome Atlas (TCGA). We ob-
served that while fibrotic liver tissue is largely devoid of DNA CNAs, highly 
frequently occurring DNA CNAs are found in mouse tumors, which is indicative 
of a profound increase in chromosomal instability in HCC. The cross- species 
gene- level comparison of CNAs identified shared regions of CNAs between hu-
man fibrosis- and cirrhosis- associated liver tumors and mouse fibrosis- associated 
HCC. Our results suggest that CNAs most commonly arise in neoplastic tissue 
rather than in fibrotic or cirrhotic liver, and demonstrate the utility of this 
mouse model in replicating the molecular features of human HCC.
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HCC is a complex and heterogeneous disease, and while 
the histopathological features of HCC are well established, 
the molecular mechanisms that drive the main etiological 
factors, including cirrhosis- causing factors, are not well 
characterized [5, 6]. Most human cases of HCC develop 
in a background of fibrosis or cirrhosis; therefore, char-
acterizing the cellular and tissue features in which tumors 
develop is as important as identifying the specific genes 
and pathways that are involved in tumorigenesis. Thus, 
mouse models that emulate human liver diseases that lead 
to HCC offer great value in the study of hepatocellular 
carcinogenesis [7]. In addition, understanding the molecu-
lar mechanisms that promote pathogenesis and progression 
of HCC will contribute to effective prevention, as well 
as the development of new therapies [8].
Many mouse models of HCC have been previously 
developed and demonstrate varying levels of similarity to 
human disease [7]. A commonly used mouse liver cancer 
model is a single low- dose injection of the genotoxic 
carcinogen N- nitrosodiethylamine (DEN) into 14- day- old 
male B6C3F1 mice [9]. Additionally, repeat dosing with 
the profibrogenic agent carbon tetrachloride (CCl4) results 
in the development of HCC [10]. The combination of 
genotoxic, for example, DEN, and nongenotoxic, for exam-
ple, CCl4, insults has been used to emulate the comorbidity 
features often observed in human HCC patients, and offers 
a relevant model to study the mechanisms involved in 
hepatocellular carcinogenesis [11]. Using this mouse model, 
we found that epigenetic alterations indicative of genomic 
instability were prevalent in both tumors and nontumor 
fibrotic tissues of mice treated with DEN+CCl4 compared 
with liver tissue of vehicle- treated control animals [12]. 
Chromosomal instability, a condition that results in DNA 
copy number alterations (CNAs), can occur simultaneously 
with and promote genomic instability [13], one of the 
“hallmarks of cancer” [14]. Therefore, we hypothesized 
that CNAs are frequent in mouse liver tumors that devel-
oped in fibrotic tissue. Furthermore, due to numerous 
pathological features shared between human HCC and 
tumors arising in this mouse model, we posit that many 
CNAs are shared (i.e., conserved) between both species.
An association between changes in DNA copy number 
values and the development and progression of cancer has 
been observed in various types of cancer, in mouse models, 
and in human clinical samples [6, 15–18]. These CNAs 
are thought to represent a type of oncogenic driver in the 
progression of cancer [19]; for example, sites of DNA copy 
number gains are known to harbor oncogenes, while sites 
of DNA copy number losses include tumor suppressor 
genes [15, 16]. Somatic DNA alterations are frequent in 
cancer, and recurrent CNAs represent one type of genetic 
aberration commonly involved in many types of cancer 
[20]. CNAs are associated with complex diseases by various 
molecular mechanisms, including gene dosage, gene disrup-
tion, and gene fusion [21, 22]. CNAs are frequently observed 
in clinical cases of HCC [6, 16, 23], and studies have 
shown similarities in the frequency and recurrence of CNAs 
in mouse and human HCC [17]. However, the exact mecha-
nistic role of DNA CNAs in carcinogenesis remains unclear.
In this study, publicly available data from human HCC 
patients and data collected from a controlled in vivo 
mouse experiment were utilized in the analysis of CNAs. 
To this end, the translational approach enabled (1) the 
characterization of chromosomal instability in HCC in a 
background of liver fibrosis, (2) the identification of genes 
within copy number-altered segments that overlap between 
clinical and experimental conditions, and (3) the associa-
tion of transcriptional response with DNA CNAs.
Materials and Methods
Animals
The in- life portion of this study, mouse treatments, tissue 
collection protocols, and incidence of neoplastic liver lesions 
are detailed in Uehara et al. [11]. The exact protocol for 
the mouse model of fibrosis- associated hepatocarcinogenesis 
is detailed in Uehara et al. [24]. Those studies were conducted 
with approval from the Institutional Care and Use Committee 
at the University of North Carolina at Chapel Hill. In the 
present work, analyses were conducted using frozen liver 
(normal, tumor and nontumor fibrotic tissues) samples col-
lected from male B6C3F1/J mice injected i.p. with DEN 
(1 mg/kg) in sterile phosphate buffered saline (PBS; 15 mL/
kg) at 2 weeks of age, followed by i.p. injections with CCl4 
(0.2 mL/kg) diluted in sterile olive oil two times per week 
for an additional 14 weeks beginning at 8 weeks of age. 
Control mice were injected with sterile PBS and sterile olive 
oil only. All mice were killed at 22 weeks of age.
DNA extraction and array comparative 
genomic hybridization
Genomic DNA was extracted from frozen liver samples 
from vehicle control and DEN+CCl4- treated mice using 
a DNEasy kit (Qiagen, Valencia, CA). Eighteen mouse 
tumor samples were included in the study, as well as 18 
matched nontumor samples taken from fibrotic, nontu-
morous, surrounding liver tissue. Liver DNA from 6 vehicle 
control mice was pooled and used as the reference genome 
in the aCGH experiments. Genomic DNA was prepared 
and hybridized to a SurePrint G3 4 × 180K Mouse Genome 
CGH Microarray (Agilent Technologies, Santa Clara, CA), 
which included content sourced from the UCSC mm9 
(NCBI Build 37), according to the manufacturer’s instruc-
tions and a 2- color/sample strategy.
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Normalization and segmentation of array 
data
For the mouse copy number data, all mouse tumor samples 
were assayed versus the pooled liver DNA from vehicle 
control mice and the R/G ratio was obtained, which is 
the relative measure of DNA copy number. The R/G ratios 
were lowess (locally weighted scatterplot smoothing) nor-
malized, followed by segmentation using SWITCHdna [15].
For the human copy number data, publically available 
circular binary segmented (CBS) [25] copy number data 
obtained from Affymetrix 6.0 SNP arrays were downloaded 
through The Cancer Genome Atlas (TCGA) data portal 
(https://tcga-data.nci.nih.gov/tcga/). The following inclu-
sion criteria were applied to select the samples for the 
analysis: (1) a diagnosis of either cirrhosis or fibrosis as 
detailed in the pathology report of the patient and (2) 
available circular binary segmented copy number data for 
both a tumor and a nontumor liver specimen.
Identification of group- specific CNAs and 
species- conserved CNAs
To identify and highlight frequently occurring CNAs 
within an assigned group, SWITCHdna [15] implements 
a postsegmentation plotting function. Specifically, seg-
mented data from samples within an assigned class (mouse 
tumor, mouse matched nontumor, human fibrosis- 
associated tumor, human cirrhosis- associated tumor, and 
human matched nontumor) were titled to highlight the 
overlapping gain and loss segments, and the frequency 
of overlapping altered genomic regions was calculated 
relative to all samples within the group. Group- specific 
and conserved CNAs were identified using the add- on 
script to SWITCHdna, called SWITCHplus (https://
genome.unc.edu/SWITCHplus/) [18]. SWITCHplus uses 
the identified copy number–altered segments from 
SWITCHdna and/or any other copy number change point 
detection tools, species- specific genomic annotations, and 
categorical information (e.g., tissue type or disease state) 
to identify frequent CNAs that are significantly associated 
with a group (e.g., tumors) compared against all other 
samples (e.g., nontumor liver). Conserved CNAs are 
identified by SWITCHplus using gene- level copy number 
data and remapping of orthologous genes (i.e., mouse 
genes remapped in human genomic order) to highlight 
overlapping features (i.e., CNAs that occur at a high 
frequency and are altered in the same direction of copy 
number gain or loss). This analysis was conducted in 
tumor and matched nontumor samples in both humans 
and mice, as well as between tumors from patients with 
HCC and cirrhosis versus tumors from patients with 
HCC and fibrosis.
Gene expression
Total RNA was extracted from frozen tumor and non-
tumor fibrotic liver from mice treated with DEN+CCl4, 
as well as normal liver of vehicle control mice using a 
Qiagen RNeasy kit according to the manufacturer’s instruc-
tions (Qiagen). RNA was reverse- transcribed (Applied 
Biosystems, Carlsbad, CA) and gene expression was deter-
mined by quantitative reverse- transcription PCR (qRTPCR) 
using gene expression assays (Applied Biosystems). We 
selected a representative set of genes that were present 
in copy number–altered segments in tumors from 
DEN+CCl4- treated mice and in CNA segments in tumors 
from human cirrhosis patients, as identified by 
SWITCHplus. From this list of common CNA- associated 
genes, a subset of genes known to be associated with 
hepatocellular carcinogenesis (Akt1, Map3k6, Rara, Tnf, 
Vegfa, Wnt1, Wnt10b, Tgfb1, and Tgfbr2) or playing a 
key role in pathways associated with HCC (Erbb2, Jrk, 
and Tgfbr1) or DNA damage and repair response (Gadd45b 
and Xrcc1) were selected for expression analysis. All genes 
and primers are listed in Table S1. Reactions were per-
formed in a 96- well assay format using a 7900HT Fast 
Real- Time PCR System (Applied Biosystems), and each 
sample was run in duplicate. The mRNA level of the 
housekeeping gene Gusb1 was evaluated in tandem with 
the experimental runs, and the relative amount of each 
mRNA transcript was determined using the 2−ΔΔCt method 
[26]. Differences in expression between liver tissue of 
control mice and tumors from DEN+CCl4- treated mice 
were evaluated by an unpaired Student’s t- test using 
GraphPad Prism 5 software (San Diego, CA), followed 
by false discovery rate (FDR) correction. Results are pre-
sented as mean ± SD. FDR- corrected P < 0.1 was con-
sidered significant.
Human RNA- seq data were downloaded from TCGA 
(http://cancergenome.nih.gov/). Genes that were differen-
tially expressed in the tumors relative to matched nontumor 
samples from cirrhosis patients were identified using the 
R package DESeq2 [27], with Benjamini–Hochberg- 
corrected P < 0.1 considered significant. Gene Set 
Association Analysis for RNA- Seq (GSAASeqSP) [28] was 
used to identify enriched genesets among the differentially 
expressed genes in human HCC.
Results
Identification of genomic segments with 
CNAs in mouse fibrosis- associated tumors
The first objective of this study was to characterize CNAs 
in both liver tumors and nontumor fibrotic liver tissue 
in a mouse model of fibrosis- associated HCC [20]. We 
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found that CNAs were much more frequent in tumors 
(Fig. 1A) than in surrounding fibrotic liver tissue (Fig. 1B). 
Copy number gains were predominant in the tumors, a 
pattern that is common in other tumor types [29], while 
both gains and losses were observed (albeit it at very low 
frequencies) in the nontumor tissues. Several segments 
of copy number gain were identified as specific to the 
tumor samples (segment copy number altered at a fre-
quency of ≥15% and contain at least one gene with a 
P- value < 0.05, highlighted as “group- specific” segments 
in Fig. 1A). In contrast, only one such segment was found 
in the nontumor tissue on Chr 10 (Fig. 1B).
CNAs in human HCC associated with 
cirrhosis or fibrosis
Another objective of our study was to compare CNAs in 
the mouse fibrosis- associated tumors with those observed 
in human cirrhosis- or fibrosis- associated HCC. Copy 
number data from 49 human HCC samples (30 patients 
with cirrhosis and 19 patients with fibrosis) were analyzed. 
The overall CNA profile of the tumors that arose in either 
cirrhotic (Fig. 2A) or fibrotic (Fig. 2B) livers was similar, 
but not identical. Of the chromosomal gains and losses 
found in our analysis, many are known to be frequent 
in HCC, such as loss of 1p, 8p, and 17p and gain of 1q, 
6p, 8q, and 20q [30]; however, we show that these effects 
are independent of whether HCC arises in the background 
of fibrosis or cirrhosis. Matched nontumor (cirrhotic or 
fibrotic) liver samples were available for a subset (n = 16) 
of these 49 patients. In these nontumor tissues, no frequent 
(present in at least 15% of the samples) copy number- 
altered segments were identified (data not shown), similar 
to our observation in the mouse model (Fig. 1B).
To identify segments with CNAs that were specific either 
to fibrosis- or cirrhosis- associated HCC in human patients, 
copy number data were analyzed in the same manner as 
in the mouse comparative analysis between tumor and 
nontumor DNA. Several segments were significantly dif-
ferent between these groups (highlighted as “group- specific” 
segments in Fig. 2). The segments that were identified as 
specific to fibrosis- or cirrhosis- associated HCC varied in 
size and position and, thus, potentially affected genes that 
were colocated in neighboring genomic regions, which 
may be particularly prone to chromosomal instability.
Cross- species comparative analysis
Next, the mouse and human CNAs were compared to 
identify conserved segments between the mouse and human 
HCC (Fig. 3A). For this analysis, we focused on human 
cirrhosis- associated HCC because the CNAs profile was 
largely similar between fibrosis- and cirrhosis- associated 
tumors. Fifty- one percent of copy number- altered segments 
Figure 1. SWITCHplus plots of mouse tumor (A) and matched nontumor fibrotic liver samples (B). The above plots show the frequency of regions with 
copy number alterations (CNAs) among the sample set of 18 mice, plotted in genomic order. CNAs were more frequent in tumors (top panel) than 
in samples from matched fibrotic liver tissue. Regions that are significantly different between the two types of tissue and also appear at a frequency 
of at least 15% are highlighted.
A
B
578 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
G. Chappell et al.Copy Number Alterations in Human and Mouse HCC
observed in the mouse tumor DNA contained at least 
one gene that was also present in a segment observed at 
a frequency of 15% or greater in the human tumor 
samples from cirrhosis patients with HCC (green segments 
in Fig. 3A). Of all the genes in these segments, one third 
(33%) was common between mouse and human HCC.
Figure 2. SWITCHplus plots of liver tumors from HCC patients with cirrhosis (A) or fibrosis (B). Regions that are significantly different between the 
two groups and also appear at a frequency of at least 15% are highlighted.
A
B
Figure 3. (A) Comparative analysis of human and mouse copy number alterations (CNAs) with homologous genes: mouse segments remapped in 
human genomic order and compared to all gains/losses in tumors from human cirrhosis patients. Segments with CNAs that include homologous 
genes between groups (human cirrhosis and mouse tumor) are highlighted. (B) Segments containing genes present in a segment in at least 15% of 
the tumor samples from human patients with cirrhosis and also present in a mouse tumor segment and that had significantly different mRNA levels 
(q < 0.10) are highlighted. The background SWITCHplot is that of human cirrhosis- associated tumor data.
A
B
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Gene expression analysis
To evaluate the relationship between CNAs and gene expres-
sion, transcript abundance was compared for a set of genes 
that were found to be gained in copy in both human and 
mouse liver tumors. For the mouse study, we selected 13 
genes to test, based on their location in segments of copy 
number gain in mouse and human in our study, as well 
as their known association with carcinogenesis [31]. Of 
these genes, 5 had an increased level of mRNA compared 
to that from control mice, 2 were down- regulated, and 6 
were not affected (Fig. 4). It is worth noting that the 
expression of two additional genes tested but not shown, 
Wnt1 and Wnt10b, was detectable in the mouse tumor 
tissues, but was below the limit of detection in the con-
trols; thus, while the relative analysis was not possible, 
these genes were also up- regulated. In contrast, when 
expression of the affected genes was tested in nontumor 
fibrotic mouse liver tissue, no change in expression relative 
to the controls was observed (data not shown).
In human cirrhosis- associated tumor samples, 52% of 
the significantly up- regulated (FDR- corrected P < 0.1) 
genes were also present in segments of gain, and 52% 
of the significantly down- regulated genes (FDR- corrected 
P < 0.1) were located in segments of copy number loss 
(Fig. 3B). To evaluate the significance of these findings 
relative to the expected outcome of a randomly chosen 
set of genes among all expressed transcripts (17,021), we 
conducted a permutation- based analysis with the gene 
set sizes corresponding to the number of significantly 
down- and up- regulated genes (2374 and 3063, respec-
tively). The distributions of the percentage of genes that 
fall into a segment of copy number gain or loss over 
1000 permutations are shown in Figure 5. Based on a 
z- score derived from the distribution of the permutated 
percentages, we found that there is zero likelihood that 
the observed concordance between CNAs and the cor-
responding gene expression changes in human HCC was 
due to chance (Fig 5).
Figure 4. Expression of a subset of genes located in segments of copy number gain in fibrosis- associated HCC in mice. mRNA level is shown as fold 
change relative to vehicle control mice, as evaluated by qRTPCR. Results are presented as mean ± SD, n = 5 for control group, n = 18 for tumor 
samples. *FDR- corrected P- value < 0.10.
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In addition, we identified enriched genesets among all 
of the differentially expressed genes in human tumors 
that were also present in CNA segments in the associated 
direction (up- regulated genes in gained segments and 
down- regulated genes in loss segments), as well as among 
all differentially expressed genes (regardless of association 
with a CNA segment). We found very similar enriched 
genesets among all genes, compared with enriched genesets 
among the subset of genes that were found within a copy 
number altered segment. For up- regulated genes, the most 
significant enriched genesets were associated with cell cycle 
processes and mitosis. For down- regulated genes, the most 
significant enriched genesets included immune and defense 
responses, as well as inflammatory response and receptor 
activity (Table S2).
To determine the degree of conservation in affected 
segments between species, we examined whether differ-
entially expressed genes in human HCC have homologs 
in the genomic regions of gain or loss in mouse HCC. 
We found that among the genes significantly (FDR- 
corrected P < 0.1) up- or down- regulated in human 
cirrhosis- associated tumors, 30.4% and 22.0% were con-
served in the segments that were gained or lost, respec-
tively, in a concordant manner in both mouse and human 
tumors. The shared percentages of each of the above- 
described comparisons are detailed in Table 1, as well as 
the percentage of genes that were differentially expressed 
in the “opposite” direction of the associated copy number 
altered segment.
Discussion
Hepatocellular carcinogenesis is a complex process that 
is the consequence of multiple molecular events that lead 
to initiation, promotion, and progression [5, 6, 8]. The 
importance of a distinct set of events that are required 
for carcinogenesis has been emphasized [14, 32], and 
distinct cellular capabilities that enable tumorigenesis, or 
“hallmarks of cancer,” are increasingly recognized as essen-
tial processes in carcinogenesis [33]. To gain a compre-
hensive perspective of the mechanisms involved in specific 
cancer types, as well as various etiologies within a type 
of cancer, investigation of underlying molecular factors 
of cancer should consider genetic aberrations, epigenetic 
alterations, changes in gene expression, and CNAs. While 
many CNAs have no apparent influence on phenotype, 
Figure 5. Histograms of the percentage of genes that are present in segments of copy number gain (A) or loss (B) over 1000 permutations of all of 
the genes expressed in the human HCC patients. The randomly permuted gene set sizes were 3063 and 2374, which are the true numbers of 
significantly up- and down- regulated genes, respectively. Arrows highlight the percentage of differentially expressed (FDR- corrected P- value < 0.10.) 
genes that are also within copy number alterations segments in the concordant direction.
A B
Table 1. Percent of differentially expressed genes (FDR- corrected 
P < 0.1) that are located in copy number altered segments, respective of 
direction of gene expression and DNA copy number.
CNA type
Gene up- 
regulation (%)
Gene down- 
regulation (%)
Human copy number gain 52.0 18.2
Human copy number loss 30.1 52.0
Species- conserved copy 
number gain
30.4 0.8
Species- conserved copy 
number loss
12.8 22.0
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others have been definitively linked with disease, including 
cancer [34]. Furthermore, structural and numerical chro-
mosomal changes occur in the majority of cancer cells 
[35].
An important consideration of the multistep process 
of carcinogenesis is that the standard mutation rate can-
not explain the extensive number of mutations present 
in many types of cancer cells [36–38]. The acquisition 
of some form of chromosomal instability is likely a nec-
essary event in tumor development that occurs relatively 
early and presents an explanation of the numerous karyo-
typic aberrations that are often observed in malignant 
tumors [17]. The subsequent process of clonal expansion 
by a stepwise accumulation of numerical chromosome 
changes would, at least in some cases, be expected to 
give rise to subpopulations of neoplastic cells related by 
the same karyotypic abnormalities [39].
Our study provides additional mechanistic information 
on the role of CNAs in HCC, both in human and mouse 
disease associated with fibrotic changes. Specifically, we 
found that while CNAs are common in liver tumors in 
both mice and humans, they are very infrequent in the 
nontumor cirrhotic or fibrotic liver in both species, sug-
gesting that CNAs are not a feature of precancerous liver 
tissue. Cirrhosis and fibrosis, the result of chronic inflam-
mation and subsequent myofibroblast activation, are con-
sidered to be involved in the promotion of carcinogenesis 
[40]. Changes in the composition of the extracellular 
matrix and in nonparenchymal cellular activity lead to 
the promotion of growth and inhibition of apoptosis in 
the hepatic cellular environment. The profound lack of 
CNAs in the nontumorous fibrotic liver tissue in both 
human and mouse samples, a pretumorous stage of liver 
disease [41], and in cirrhotic liver tissue in humans, is 
a novel finding. If CNAs do, in fact, exist in the sur-
rounding fibrotic or cirrhotic tissue of the liver, perhaps 
the accumulation of the CNAs is contingent upon clonal 
expansion and increased genomic instability in tumor 
tissue.
In relation to our previous findings of epigenetic altera-
tions in both tumor and fibrotic surrounding tissue, as 
well as a lack of mutations commonly observed in HCC 
in both humans and mice in the same mouse tissues 
discussed herein [12], we posit that epigenetic alterations 
indicative of genomic instability precede CNAs. Further, 
these findings suggest that CNAs occur relatively early in 
the carcinogenic process compared to common activating 
or inactivating mutations, which is consistent with other 
reports of chromosomal instability as an early event in 
tumorigenesis [17, 38]. In concordance with the findings 
of a recent study that evaluated the association between 
chromosomal instability and global DNA hypomethylation 
in human HCC samples [42], we observed CNAs in the 
same tissues in which epigenetic alterations that are indica-
tive of genomic instability were observed. Although the 
mechanistic link between these two phenotypes is not 
clear, one potential explanation that has been proposed 
suggests that activation of hypomethylated repetitive DNA 
elements within genes may cause chromosomal rearrange-
ments [43], a supposition that is further supported by 
the fact that both chromosomal instability and epigenetic 
alterations are generally considered early events in car-
cinogenesis [12, 17, 38].
An important outcome of the present study is the 
demonstration of the relevance of the mouse fibrosis- 
associated liver cancer model to human HCC. Although 
the liver is the most common tissue for tumor develop-
ment in experimental rodent studies of chronic exposure 
to xenobiotics [44], most chronic rodent cancer studies 
fail to induce liver fibrosis or cirrhosis, which is the most 
common histopathological feature observed in HCC 
patients and is an important mechanism of hepatocar-
cinogenesis [3]. In the present study, many segments with 
altered copy number, as well as the genes within those 
segments, were observed in tumors from both mouse and 
human HCC. Mouse models that employ chemically 
induced carcinogenesis display a varying degree of similar-
ity to human disease and may be well (or poorly) cor-
related with specific human etiologies, risk factors, or 
subclasses. The mouse model used herein has been reported 
to share many of the characteristics generally observed 
in cirrhosis- associated human HCC, including, but not 
limited to, inflammatory response and fibrogenesis [11]. 
Up- regulation of mRNA markers of inflammation and 
fibrosis have been previously reported in the fibrotic non-
tumor tissues [11, 45], as well as in tumor tissue in the 
present study (Tnf, Tgfβ1, Tgfbr1, and Tgfbr2). The human 
samples included in the present study had various etiolo-
gies of HCC, including hepatitis B and C infection, non-
alcoholic fatty liver disease, and alcohol consumption. 
These etiological factors, among other clinical data, are 
detailed in Table S3. We used all of the TCGA data 
available at the time that met our inclusion criteria described 
in Materials and Methods, which included various etiolo-
gies. It is possible that in a larger study conducted in 
the future, we may be able to compare our mouse model 
to a specific subcategory of human HCC. In the present 
study, the CNA profile for HCC occurring in a background 
of fibrosis or cirrhosis, regardless of etiology, was of pri-
mary interest.
The next important outcome of this work is in the 
examination of the concordance among CNAs and gene 
expression. Altered gene expression has been previously 
shown to occur in approximately half of the genes with 
CNAs in human cancer studies, both in clinical samples 
[46, 47] and in in vitro studies with immortalized human 
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cell lines [48]. These results, together with findings in 
our study, indicate that CNAs can and do alter gene 
expression, but that this particular mechanism of altered 
gene expression is tumor- and tissue- type specific. A study 
of human breast tumors [46] concluded that approximately 
12% of variation in mRNA levels was directly attributed 
to CNAs, although the authors posited that their finding 
“represents a significant underestimate” due to the con-
servative nature of the analysis, global variation in tumor 
cells, and the presence of nontumor cells in the samples. 
We found that 38% of the genes we evaluated in the 
mouse tumors were significantly differentially expressed 
in the associated direction of a copy number-altered seg-
ment. However, we found a higher concordance between 
differentially expressed genes and CNAs in the human 
cirrhosis- associated tumors (52% for both gain and loss). 
This discrepancy between species is likely due to the much 
more comprehensive analysis that was possible for the 
human samples, afforded by the RNA- sequencing data 
available through TCGA. The enrichment of mitosis and 
cell cycle genesets is correlative with increased prolifera-
tion in the tumor cells, and the loss of immune response 
and cellular defense genes observed in the present study 
has also been previously reported in HCC, particularly 
in cases of viral hepatitis [49]. The overrepresentation of 
cell cycle process genesets corroborates with the increased 
proliferation expected in the scenario of angiogenesis, 
although it cannot be concluded with certainty that these 
genesets are enriched due to their association with increased 
or decreased copy number, or if the CNAs are due to 
the enrichment of these mitosis- related genesets. An 
increase in cell cycle processes in conjunction with chro-
mosomal instability may represent a driver in the excessive 
CNAs observed in these tumors.
In a recent review of genetic alterations in HCC [50], 
“telomere maintenance” was identified as one of the driver 
pathways recurrently altered in HCC. This pathway includes 
TERT (telomerase reverse transcriptase), which is the most 
frequently mutated gene in human HCC, has been shown 
to be amplified in DNA copy number in HCC and is 
dysregulated in cirrhotic liver. In our study, TERT was 
increased in copy number in the human tumor samples, 
and the gene expression was also significantly up- regulated. 
In the mouse samples, however, the Tert gene was not 
increased in DNA copy number, suggesting that this gene 
is more subject to CNA in humans than in mice.
It is essential to consider various mechanisms of gene 
regulation when evaluating the role of specific genes in 
cancer and when making assumptions based on copy 
number. For example, Vegfa is a gene commonly up- 
regulated in cancer and was present in a frequently gained 
segment in both mouse and human HCC in our sample 
sets. However, Vegfa gene expression was actually 
significantly down-regulated in the mouse tumor samples. 
This loss of expression of Vegfa is in contrast to previous 
reports of DEN- induced mouse liver tumors [51], and 
could be explained by the up- regulation of Tgfb1 observed 
in our study, a gene that has been shown to inhibit Vegfa. 
Tgfb1 is also located in a segment of copy number gain 
in the mouse tumors, and the mRNA level was signifi-
cantly increased in the mouse tumors. Further, Vegfa was 
found to be up- regulated in nontumor surrounding liver 
tissue in the mouse samples, alternatively suggesting that 
the expression of this gene is not directly controlled by 
CNA copy number in this mouse model (data not shown). 
Considering the number of genes that were regulated in 
a manner opposite of DNA copy number, many such 
complexities may exist in both species.
The limitations of this study should be noted. While 
it is widely accepted that HCC is a heterogeneous cancer 
that presents diverse molecular profiles across patients (or 
animals), as well as within an individual (or animal) in 
some cases [50, 52], genomic DNA from only one tumor 
from each mouse was used in our study. Tumor hetero-
geneity is thought to occur from the same selective pro-
cesses that lead to common CNAs [18, 53]: cells with 
genomic imbalances proliferate and accumulate, they 
acquire new mutations and CNAs [37], and clonal expan-
sion may occur at slightly different points in the evolution 
of that clonal cell line. Interpatient, as well as interanimal, 
heterogeneity was of less concern because the goal of the 
present study was to find the most common CNAs among 
a set of tumors that were assumed to have some level 
of heterogeneity. Regarding the human HCC data, similar 
to the above- mentioned rationale, while interpatient het-
erogeneity is extremely important, this study aimed to 
identify common CNAs among HCC patients with fibrosis 
and cirrhosis.
In conclusion, our results demonstrate an accumulation 
of CNAs in liver tumors in a mouse model of fibrosis- 
associated HCC, a finding that, together with previous 
results demonstrating increased epigenetic alterations 
indicative of genomic instability, suggests that chromosomal 
instability is a feature of tumor cells that precedes com-
mon mutations. CNAs were more prevalent in tumors 
compared to surrounding fibrotic or cirrhotic liver tissue 
in both mice and humans, indicating that chromosomal 
instability is a feature specific to neoplastic rather than 
preneoplastic tissue in cases of HCC. Approximately half 
of the frequently gained or lost segments observed in the 
mouse fibrosis- associated liver tumors and approximately 
one third of the copy number- altered genes were also 
observed in human cirrhosis-associated HCC samples. This 
demonstrates the similarity in genomic features between 
this mouse model of HCC and that of liver tumors in 
human patients with cirrhosis- associated HCC.
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